| Old Articles: <Older 7901-7910 Newer> |
|---|
 |
The Motley Fool
June 16, 2005
Rick Aristotle Munarriz |
Mamma's Own Cooking Mamma.com puts its idle cash to work with a share buyback. Hopefully, this month's buying binge means that Mamma is done with its spendthrift ways when it comes to issuing new stock.   |
The Motley Fool
June 16, 2005
Selena Maranjian |
Sell Your Stuff -- Like Stocks Clear out clutter and enjoy the things you really value even more. That applies to your portfolio, too. Clear out the clutter and gaze admiringly at the companies you really like. |
The Motley Fool
June 15, 2005
W.D. Crotty |
Viacom: It's Twins! Viacom board approved the company's split into two. With its high quality assets and low earnings multiple, the twin stocks are poised to reward patient investors. |
The Motley Fool
June 15, 2005
Bobby Shethia |
A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note. |
The Motley Fool
June 15, 2005
Charly Travers |
Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success. |
The Motley Fool
June 15, 2005
Rich Duprey |
Counting Sheep With Select Comfort's Numbers? Company says sales and revenues are on target, but it has a shoddy record of prognostication. Investors, take note. |
The Motley Fool
June 15, 2005
Alyce Lomax |
R.I.P. VHS Is the writing on the wall for the VHS standard? To investors, decisions like Wal-Mart's and Target's speak directly to good old-fashioned supply and demand, peddling the inventory that's going to move. |
The Motley Fool
June 15, 2005
Steven Mallas |
Why Atari's Still Not a Buy Atari delivers its latest quarterly report, and it isn't that exciting. Neither is the stock. |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
The Motley Fool
June 15, 2005
Rich Smith |
Nietzsche on Investing With investing comes risk. In the short term, you will definitely lose money on some of your stocks at one time or another. But that which does not kill you as an investor makes you stronger. |
| <Older 7901-7910 Newer> Return to current articles. |
